sonar-pro
Permits stability data submission for pharmaceutical products at 25°C/60% relative humidity (RH) when supported by accelerated stability studies.
{
  "id": "903eb6bf-b3a7-4faf-8f7e-e751239dabbe",
  "choices": [
    {
      "finish_reason": "stop",
      "index": 0,
      "logprobs": null,
      "message": {
        "content": "{\"answer\":\"NO\",\"note\":\"Singapore does not permit stability data submission at 25°C/60% RH as the primary long-term condition for pharmaceutical products. According to current guidelines for Singapore (referencing the Health Sciences Authority and ASEAN guidelines), Singapore follows the ASEAN stability guideline, which requires long-term stability studies to be conducted at 30°C ± 2°C/75% RH ± 5% RH. This reflects Singapore's classification as a hot and humid (climatic zone IVb) country. Data at 25°C/60% RH is not sufficient, even if supported by accelerated stability studies. Required long-term studies must be at the local climatic condition; 25°C/60% RH is more appropriate for temperate (zone II) markets, not for Singapore[5][1].\"}",
        "refusal": null,
        "role": "assistant",
        "annotations": null,
        "audio": null,
        "function_call": null,
        "tool_calls": null
      },
      "delta": {
        "role": "assistant",
        "content": ""
      }
    }
  ],
  "created": 1755743972,
  "model": "sonar-pro",
  "object": "chat.completion",
  "service_tier": null,
  "system_fingerprint": null,
  "usage": {
    "completion_tokens": 167,
    "prompt_tokens": 31,
    "total_tokens": 198,
    "completion_tokens_details": null,
    "prompt_tokens_details": null,
    "search_context_size": "low",
    "cost": {
      "input_tokens_cost": 0.0,
      "output_tokens_cost": 0.003,
      "request_cost": 0.006,
      "total_cost": 0.009
    }
  },
  "citations": [
    "https://asean.org/wp-content/uploads/i-Final-ASEAN-Guideline-on-Stability-Study-Drug-Product-R2_uniformed-template.pdf",
    "https://database.ich.org/sites/default/files/Q1F_Stability_Guideline_WHO_2018.pdf",
    "http://academy.gmp-compliance.org/guidemgr/files/WHO_TRS_953_Annex2.pdf",
    "https://www.rsc.org/suppdata/c5/ra/c5ra07716h/c5ra07716h1.pdf",
    "https://www.hsa.gov.sg/docs/default-source/hprg-tpb/guidances/guidance-on-therapeutic-product-registration-in-singapore.pdf?sfvrsn=cd174383_52"
  ],
  "search_results": [
    {
      "title": "[PDF] ASEAN GUIDELINE ON STABILITY STUDY OF DRUG PRODUCT",
      "url": "https://asean.org/wp-content/uploads/i-Final-ASEAN-Guideline-on-Stability-Study-Drug-Product-R2_uniformed-template.pdf",
      "date": null,
      "last_updated": "2025-08-10"
    },
    {
      "title": "[PDF] Annex 10 - ICH",
      "url": "https://database.ich.org/sites/default/files/Q1F_Stability_Guideline_WHO_2018.pdf",
      "date": null,
      "last_updated": "2025-08-10"
    },
    {
      "title": "[PDF] Annex 2 Stability testing of active pharmaceutical ingredients and ...",
      "url": "http://academy.gmp-compliance.org/guidemgr/files/WHO_TRS_953_Annex2.pdf",
      "date": null,
      "last_updated": "2025-08-10"
    },
    {
      "title": "[PDF] Annex 2 Stability testing of active pharmaceutical ingredients and ...",
      "url": "https://www.rsc.org/suppdata/c5/ra/c5ra07716h/c5ra07716h1.pdf",
      "date": null,
      "last_updated": "2025-03-27"
    },
    {
      "title": "[PDF] guidance-on-therapeutic-product-registration-in-singapore.pdf",
      "url": "https://www.hsa.gov.sg/docs/default-source/hprg-tpb/guidances/guidance-on-therapeutic-product-registration-in-singapore.pdf?sfvrsn=cd174383_52",
      "date": null,
      "last_updated": "2025-08-12"
    }
  ]
}